Kaplan Andrew T.
SEC Form 4 insider trading activity
Kaplan Andrew T. has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Apr 20, 2026.
On the most recent filing, Kaplan Andrew T. is listed as Director, 10% Owner at Kailera Therapeutics, Inc. Inside the rolling window, Kaplan Andrew T. reported 1 open-market purchase totaling $134.4M in KLRA and no open-market sales.
Companies traded
Other insiders at KLRA
Insider Buying
$134.4M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kaplan Andrew T. made?
Kaplan Andrew T. has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.
Which companies does Kaplan Andrew T. trade?
Kaplan Andrew T. has filed SEC Form 4 disclosures for 1 company, including KLRA.
When was Kaplan Andrew T.'s most recent SEC Form 4 filing?
Kaplan Andrew T.'s most recent SEC Form 4 filing on Tracefour is dated Apr 20, 2026.
What is Kaplan Andrew T.'s total buy and sell value in the current window?
Inside the rolling retention window, Kaplan Andrew T. bought $134.4M and sold $0 based on SEC Form 4 filings.
What was Kaplan Andrew T.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 8,398,438 KLRA shares on 2026-04-20, worth $134.4M, per SEC Form 4 filings.